Last reviewed · How we verify
NCT07302763: 4TMPO
Four-Timepoint Multi-tracer PET Imaging to Characterize Metastatic prOstate Cancer Heterogeneity
NA trial testing PET Tracer in mCRPC (Metastatic Castration-resistant Prostate Cancer) in 45 participants. Currently enrolling.
31 December 2029
Quick facts
| Lead sponsor | Frederic Pouliot |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 45 |
| Start date | 4 November 2025 |
| Primary completion | 31 December 2029 |
| Estimated completion | 31 December 2030 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- PET Tracer — full drug profile →
Conditions studied
- mCRPC (Metastatic Castration-resistant Prostate Cancer) — all drugs for mCRPC (Metastatic Castration-resistant Prostate Cancer) →
Sponsor
Frederic Pouliot
Who can join
18 and older, male only, with mCRPC (Metastatic Castration-resistant Prostate Cancer). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Imaging modalities currently used in the clinics do not image cancer, but the effect ofncancer on bone (bone scan) or on the anatomy (CT-scan). Bone scan and CT-scan are therefore named conventional imaging (CI) modalities. Positron Emission Tomography (PET) is an imaging technique that uses tracers to measure cancer activity in each lesion and is therefore quantitative. Usually, treatment changes in metastatic prostate cancers are based on the appearance of new lesions on CI, named metastases. Prostate cancer metastases have been shown to be clonal, which means that there are several cancers within each patient, potentially with divergent behaviors under therapy. In other words, some metastases might be resistant to a systemic therapy like chemotherapy, while others might be sensitive. The study proposes here to use molecular imaging by positron emission tomography to image and quantify the activity of prostate cancer cells in each metastasis before start, after 3 months and after progression during systemic therapy. Each metastasis will then be measured to assess whether there is an increase (resistance) or a decrease (response) in prostate cancer cell activity. The analysis will determine how many metastases progress or remain stable when new metastases appear on conventional imaging (polyclonal resistance), as well as the impact of a change in therapy on metastases that were previously stable when cancer progressed elsewhere. In addition, the genes expressed in responding and non-responding metastases will be analyzed to identify gene expression patterns associated with resistance and/or response. Overall, this study aims to characterize metastatic prostate cancer clonal resistance mechanisms using serial PET molecular imaging and imaging-guided genomics.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07302763
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PET Tracer
Trials testing the same drug.
- NCT05615415 — Neuropsychiatric Post-Acute Sequelae of SARS-CoV-2 (PASC) Using TSPO Positron Emission Tomography (PET) and MRI · active not recruiting
Other recruiting trials for mCRPC (Metastatic Castration-resistant Prostate Cancer)
Currently open trials in the same condition.
- NCT07451795 — SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC · Phase 2 · recruiting
- NCT06801236 — Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer · Phase 1 · recruiting
- NCT06785636 — Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617 · Phase 1, PHASE2 · recruiting
- NCT06702995 — Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cance · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07302763 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Frederic Pouliot
- Last refreshed: 24 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07302763.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing